BACKGROUND: Fear of cancer recurrence (FCR) is more intense in younger women. Because FCR is a powerful determinant of quality of life, identifying those at risk for persistently elevated FCR can inform timing of interventions. METHODS: A total of 965 women with stage 0 to stage III breast cancer enrolled in the Young Women's Breast Cancer Study, a prospective cohort of women diagnosed with breast cancer at age ≤40 years, completed the 3-item Lasry Fear of Recurrence Index. Group-based trajectory modeling was used to classify distinct FCR patterns from baseline through 5 years post-diagnosis. Multinomial logistic regression was used to identify patient, disease, and treatment characteristics associated with each trajectory. RESULTS: Five FCR trajectories were identified with the majority of participants having moderate (33.1%) or high FCR (27.6%) that improved over time. A total of 6.9% participants had moderate FCR that worsened, whereas 21.7% had high FCR at baseline that remained high throughout. In the fully adjusted multinomial model, stages II and III (vs stage I) were associated with lower odds (of being in the high/stable trajectory). White (vs non-White) were associated with higher odds of being in a trajectory that improved over time. CONCLUSIONS: Although FCR improves over time for many young women with breast cancer, approximately one-third had FCR that was severe and did not improve or worsened over 5 years after diagnosis. Ongoing monitoring is warranted, with early referral to mental health professionals indicated for those at highest risk for unresolved FCR. LAY SUMMARY: Fear of recurrence is common among young women with breast cancer. The authors followed a large cohort of young women diagnosed with breast cancer when they were 40 years of age and younger, and found 5 distinct trajectories that show moderate and severe fears do not always improve over time and may require targeted mental health intervention.
BACKGROUND: Fear of cancer recurrence (FCR) is more intense in younger women. Because FCR is a powerful determinant of quality of life, identifying those at risk for persistently elevated FCR can inform timing of interventions. METHODS: A total of 965 women with stage 0 to stage III breast cancer enrolled in the Young Women's Breast Cancer Study, a prospective cohort of women diagnosed with breast cancer at age ≤40 years, completed the 3-item Lasry Fear of Recurrence Index. Group-based trajectory modeling was used to classify distinct FCR patterns from baseline through 5 years post-diagnosis. Multinomial logistic regression was used to identify patient, disease, and treatment characteristics associated with each trajectory. RESULTS: Five FCR trajectories were identified with the majority of participants having moderate (33.1%) or high FCR (27.6%) that improved over time. A total of 6.9% participants had moderate FCR that worsened, whereas 21.7% had high FCR at baseline that remained high throughout. In the fully adjusted multinomial model, stages II and III (vs stage I) were associated with lower odds (of being in the high/stable trajectory). White (vs non-White) were associated with higher odds of being in a trajectory that improved over time. CONCLUSIONS: Although FCR improves over time for many young women with breast cancer, approximately one-third had FCR that was severe and did not improve or worsened over 5 years after diagnosis. Ongoing monitoring is warranted, with early referral to mental health professionals indicated for those at highest risk for unresolved FCR. LAY SUMMARY: Fear of recurrence is common among young women with breast cancer. The authors followed a large cohort of young women diagnosed with breast cancer when they were 40 years of age and younger, and found 5 distinct trajectories that show moderate and severe fears do not always improve over time and may require targeted mental health intervention.
Authors: Julie M Cessna Palas; Kelly A Hyland; Ashley M Nelson; Brent J Small; Heather S L Jim; Paul B Jacobsen Journal: Support Care Cancer Date: 2020-06-10 Impact factor: 3.603
Authors: Jennifer L Gnerlich; Anjali D Deshpande; Donna B Jeffe; Allison Sweet; Nick White; Julie A Margenthaler Journal: J Am Coll Surg Date: 2009-01-21 Impact factor: 6.113
Authors: James L Khatcheressian; Patricia Hurley; Elissa Bantug; Laura J Esserman; Eva Grunfeld; Francine Halberg; Alexander Hantel; N Lynn Henry; Hyman B Muss; Thomas J Smith; Victor G Vogel; Antonio C Wolff; Mark R Somerfield; Nancy E Davidson Journal: J Clin Oncol Date: 2012-11-05 Impact factor: 44.544
Authors: Sophie Lebel; Christine Maheu; Christina Tomei; Lori J Bernstein; Christine Courbasson; Sarah Ferguson; Cheryl Harris; Lynne Jolicoeur; Monique Lefebvre; Linda Muraca; Agnihotram V Ramanakumar; Mina Singh; Julia Parrott; Danielle Figueiredo Journal: Psychooncology Date: 2018-09-27 Impact factor: 3.894
Authors: Nina M Tauber; Mia S O'Toole; Andreas Dinkel; Jacqueline Galica; Gerry Humphris; Sophie Lebel; Christine Maheu; Gozde Ozakinci; Judith Prins; Louise Sharpe; Allan Ben Smith; Belinda Thewes; Sébastien Simard; Robert Zachariae Journal: J Clin Oncol Date: 2019-09-18 Impact factor: 44.544